Reply

We appreciate the interest of Fouad and coworkers in our study regarding the prevalence of steatotic liver disease (SLD) in the United States.1 Our research is in line with the revised nomenclature to categorize SLD subtypes. In their recent letter to the editor, Fouad et  al2 express concerns about the newly adapted nomenclature, particularly in the context of mixed etiologies contributing to SLD. They suggest that the previously proposed nomenclature, specifically metabolic-associated fatty liver disease (MAFLD), might be superior in certain scenarios.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Tags: Letters to the Editor Source Type: research